Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) EBT (2020 - 2025)

Historic EBT for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to -$12.4 million.

  • Maxcyte's EBT fell 743.27% to -$12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.6 million, marking a year-over-year decrease of 2768.92%. This contributed to the annual value of -$41.1 million for FY2024, which is 825.88% down from last year.
  • According to the latest figures from Q3 2025, Maxcyte's EBT is -$12.4 million, which was down 743.27% from -$12.4 million recorded in Q2 2025.
  • Maxcyte's 5-year EBT high stood at -$2.7 million for Q3 2021, and its period low was -$12.4 million during Q3 2025.
  • Over the past 5 years, Maxcyte's median EBT value was -$9.4 million (recorded in 2024), while the average stood at -$8.2 million.
  • As far as peak fluctuations go, Maxcyte's EBT skyrocketed by 4275.92% in 2022, and later tumbled by 16754.85% in 2023.
  • Quarter analysis of 5 years shows Maxcyte's EBT stood at -$4.9 million in 2021, then increased by 1.33% to -$4.8 million in 2022, then dropped by 9.74% to -$5.3 million in 2023, then crashed by 100.78% to -$10.6 million in 2024, then fell by 17.17% to -$12.4 million in 2025.
  • Its EBT was -$12.4 million in Q3 2025, compared to -$12.4 million in Q2 2025 and -$10.3 million in Q1 2025.